prof. uwe platzbecker | ash 2017 | mrd guided treatment in aml: the relaza2 trial
Published 6 years ago • 743 plays • Length 2:55Download video MP4
Download video MP3
Similar videos
-
3:23
final long-term follow-up results of the relaza2 study: mrd-guided treatment with aza in mds and aml
-
4:34
prof. gail roboz | ash 2017 | new hope in aml: ngs, ch and mrd
-
2:15
prof. selina luger | ash 2017 | improving standard therapy in aml
-
3:08
aml highlights from ash 2017
-
4:04
uwe platzbecker | what are the latest treatment management strategies for patients with apl?
-
2:38
uwe platzbecker | isal 2019 | novel agents of frontline or relapsed aml therapy
-
2:19
phase i trial of ca-4948 in aml or mds
-
30:20
itp pathophysiology and diagnostic prospective – dr. mansour aljabry (sep 30-oct 1, 2022)
-
2:33
amyotrophic lateral sclerosis new stem cells treatment
-
4:11
dr. alexandre abizaid | bioresorbable vascular scaffold | meres100™ | europcr
-
3:18
what has the samba trial taught us about the treatment of elderly high-risk aml/mds patients?
-
2:08
dr. elli papaemmanuil | ash 2017 | classification and risk assessment in aml
-
1:40
long-term follow-up of luspatercept: response duration and progression to aml
-
4:20
what factors should be considered when selecting treatment for an elderly aml patient?
-
3:42
recent advances in the field of allo-hsct
-
3:23
prof. jeffrey lancet | ash 2017 | cpx-351 in aml patients with raeb-t
-
1:35
mrd: pivotal to progress in aml
-
3:24
prof. mark levis | ash 2017 | overview of flt3 inhibitors in aml
-
3:41
prof. eunice wang | ash 2017 | crenolanib and sc in young newly diagnosed flt3 mutated aml
-
2:44
prof. charles craddock | ash 2017 | key findings from the viola trial
-
1:12
medalist: os & risk of disease progression in patients with mds treated with luspatercept